Antitumor activity of interleukin 12 in preclinical models

Cancer Chemotherapy and Pharmacology, Supplement

Volumn 38, Issue , 1996, Pages

  Brunda, Michael J ^a   Luistro, Leopoldo ^a   Rumennik, Leonid ^a   Wright, Rosemary B ^a   Dvorozniak, Mark ^a   Aglione, Anthony ^a   Wigginton, Jon M ^b   Wiltrout, Robert H ^c   Hendrzak, Jill A ^a   Palleroni, Alicia V ^a  

^a HOFFMANN LA ROCHE INC   (United States)

^b SAIC FREDERICK INC   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Antitumor activity; Cytokine; Interferon; Interleukin 12; Interleukin 2

Indexed keywords

ALPHA INTERFERON; DOXORUBICIN; ETOPOSIDE; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 2;

ANTINEOPLASTIC ACTIVITY; CANCER; CONFERENCE PAPER; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 19244372276     PISSN: 09439404     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800051031     Document Type: Conference Paper

References (51)

1. Brunda MJ, Gately MK (1994) Anti-tumor activity of interleukin-12. Clin Immunol Immunopathol 71: 253
2. Brunda MJ, Gately MK (1995) Interleukin-12: potential role in cancer therapy. In: DeVita VT Jr, Hellman S, Rosenberg SA (eds) Important advances in oncology 1995. Lippincott, Philadelphia, p 3
3. Brunda MJ, Luistro L, Warrier RR, Wright RB, Hubbard BR, Murphy M, Wolf SF, Gately MK (1993) Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 178: 1223
4. Brunda MJ, Luistro L, Hendrzak JA, Fountoulakis M, Garotta G, Gately MK (1995) Role of interferon-γ in mediating the antitumor efficacy of interleukin-12. J Immunother 17: 71
5. Brunda MJ, Luistro L, Warrier R, Gately MK (1995) Antitumor activity of interleukin-12 compared to and combined with other cytokines. Proceedings, 9th international congress on immunology, San Francisco, CA, USA July 23-29, 1995, p 871
6. Brunda MJ, Luistro L, Rumennik L, Wright RB, Wigginton JM, Wiltrout RH, Hendrzak JA, Palleroni AV (1996) Interleukin-12: murine models of a potent antitumor agent. Ann NY Acad Sci (in press)
7. Cesano A, Visonneau S, Cioe L, Clark SC, Rovera G, Santoli D (1994) Reversal of acute myelogenous leukemia in humanized SCID mice using a novel adoptive transfer approach. J Clin Invest 94: 1076
8. Cesano A, Visonneau S, Santoli D (1995) Treatment of experimental glioblastoma with a human major histocompatibility complex nonrestricted cytotoxic T cell line. Cancer Res 55: 96
9. Dalton DK, Pitts-Meek S, Keshav S, Figari IS, Bradley A, Stewart TA (1993) Multiple defects of immune cell function in mice with disrupted interferon-γ genes. Science 259: 1739
10. D'Andrea A, Rengaraju M, Valiante NM, Chehimi J, Kubin M, Aste M, Chan SH, Kobayashi M, Young D, Nickbarg E, Chizzonite R, Wolf SF, Trinchieri G (1992) Production of natural killer cell stimulatory factor (interleukin-12) by peripheral blood mononuclear cells. J Exp Med 176: 1387
11. Desai BB, Quinn PM, Wolitzky AG, Mongini PKA, Chizzonite R, Gately MK (1992) IL-12 receptor. II. Distribution and regulation of receptor expression. J Immunol 148: 3125
12. Desai BB, Truitt T, Honasoge S, Warrier R, Chizzonite R, Gately MK (1993) Expression of functional IL-12R on a human IL-2-dependent T cell line. J Immunol 150: 207A
13. Emi Y, Ara G, Holden SA, Clinton S, Teicher BA (1995) Interleukin-12 (IL-12) enhances antitumor activity of chemotherapy and radiotherapy in murine models. Proc Am Assoc Cancer Res 36: 480
14. Fujiwara H, Zou J-P, Hermann S, Hamaoka T (1995) IL-12-induced tumor regression depends on a striking reversal of suppressed IFN-γ production by anti-tumor T cells, their accumulation to tumor sites and in situ IFN-γ production. Res Immunol 146: 638
15. Gately MK, MJ Brunda (1995) Interleukin-12: a pivotal regulator of cell-mediated immunity. In: Kurzrock R, Talpaz M (eds) Cytokines: interleukins and their receptors. Kluwer, Norwell, Massachusetts, p 341
16. Gately MK, Desai BB, Wolitzky AG, Quinn PM, Dwyer CM, Podlaski FJ, Familletti PC, Sinigaglia G, Chizonnite R, Gubler U, Stern AS (1991) Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotoxic lymphocyte maturation factor). J Immunol 147: 874
17. Gately MK, Wolitzky AG, Quinn PM, Chizzonite R (1992) Regulation of human cytolytic lymphocyte responses by interleukin-12. Cell Immunol 143: 127
18. Gately MK, Gubler U, Brunda MJ, Nadeau RR, Anderson TD, Lipman JM, Sarmiento U (1994) Interleukin-12: a cytokine with therapeutic potential in oncology and infectious diseases. Ther Immunol 1: 187
19. Gately MK, Warrier RR, Honasoge S, Carvajal DM, Faherty DA, Connaughton SE, Anderson TD, Sarmiento U, Hubbard BR, Murphy M (1994) Administration of recombinant IL-12 to normal mice enhances cytolytic lymphocyte activity and induces production of IFN-γ in vivo. Int Immunol 6: 157
20. Germann T, Bongartz M, Dlugonska H, Hess H, Schmitt E, Kolbe L, Kolsch E, Gately MK, Rude E (1995) IL-12 profoundly upregulates the synthesis of antigen specific complement-fixing IgG2a, IgG2b, and IgG3 antibody subclasses in vivo. Eur J Immunol 25: 823
21. Gubler U, Chua AO, Schoenhaut DS, Dwyer CM, McComas W, Motyka R, Nabavi N, Wolitzky AG, Quinn PM, Familletti PC, Gately MK (1991) Coexpression of two distinct genes is required to generate secreted, bioactive cytotoxic lymphocyte maturation factor. Proc Natl Acad Sci USA 88: 4143
22. Hendrzak JA, Brunda MJ (1995) Interleukin-12: biological activity, therapeutic utility and role in disease. Lab Invest 72: 619
23. Hendrzak JA, Brunda MJ (1996) Interferons and other cytokines. In: Teicher B (ed) Cancer drug discovery. Marcel Dekker, New York (in press)
24. Hill LL, Perussia B, McCue PA, Korngold R (1994) Effect of human natural killer cells on the metastatic growth of human melanoma xenografts in mice with severe combined immunodeficiency. Cancer Res 54: 763
25. Hiscox S, Hallett MB, Puntis MCA, Jiang WG (1995) Inhibition of cancer cell motility and invasion by interleukin-12. Clin Exp Metastasis 13: 877
26. Hsieh C-S, Macatonia SE, Tripp CE, Wolf SF, O'Garra A, Murphy KM (1993) Development of Th1 CD4 T cells through IL-12 produced by Listeria-induced macrophages. Science 260: 547
27. Kobayashi M, Fitz L, Ryan M, Hewick RM, Clark SC, Chan S, Loudon R, Sherman F, Perussia B, Trinchieri G (1989) Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biological effects on human lymphocytes. J Exp Med 170: 827
28. Manetti R, Parronchi P, Giudizi MG, Piccinni M-P, Maggi E, Trinchieri G, Romagnani S (1993) Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J Exp Med 177: 1199
29. Martinotti A, Stoppacciaro A, Vagliani M, Melani C, Spreafico F, Wysocka M, Parmiani G, Trinchieri G, Colombo MP (1995) CD4 T cells inhibit in vivo the CD8-mediated immune response against murine colon carcinoma cells transduced with interleukin-12 genes. Eur J Immunol 25: 137
30. Mayor SE, O'Donnell MA, Clinton SK (1994) Interleukin-12 (IL-12) immunotherapy of experimental bladder cancer. Proc Am Assoc Cancer Res 35: 474
31. Mu J, Zou J-P, Yamamoto N, Tsutsui T, Tai X-G, Kobayashi M, Herrmann S, Fujiwara H, Hamaoka T (1995) Administration of recombinant interleukin 12 prevents outgrowth of tumor cells metastasizing spontaneously to lung and lymph nodes. Cancer Res 55: 4404
32. Nastala CL, Edington HD, McKinney TG, Tahara H, Nalesnik NA, Brunda MJ, Gately MK, Wolf SF, Schreiber RD, Storkus WJ, Lotze MT (1994) Recombinant IL-12 administration induces tumor regression in association with IFN-γ production. J Immunol 153: 1697
33. + NK cells. J Immunol 148: 2429
34. Noguichi Y, Richards EC, Chen Y-T, Old LJ (1995) Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma. Proc Natl Acad Sci USA 92: 2219
35. O'Toole M, Wolf SF, O'Brien C, Hubbard B, Herrmann S (1993) Effect of in vivo IL-12 administration on murine tumor cell growth. J Immunol 150: 294A
36. Presky DH, Gubler U, Chizzonite RA, Gately MK (1995) IL-12 receptors and receptor antagonists. Res Immunol 146: 439
37. Schoenhaut DS, Chua AO, Wolitzky AG, Quinn PM, Dwyer CM, McComas W, Familletti PC, Gately MK, Gubler U (1992) Cloning and expression of murine IL-12. J Immunol 148: 3433
38. Skladanowski A, Konopa J (1993) Adriamycin and daunomycin induce programmed cell death (apoptosis) in tumour cells. Biochem Pharmacol 46: 375
39. Stem AS, Podlaski FJ, Hulmes JD, Pan Y-CE, Quinn PM, Wolitzky AG, Familletti PC, Stremlo DL, Truitt T, Chizzonite R, Gatley MK (1990) Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells. Proc Natl Acad Sci USA 87: 6808
40. Stern LL, Tarby CM, Tamborini B, Truitt GA (1993) Preclinical development of IL-12 as an anticancer drug: comparison to IL-2. Proc Am Assoc Cancer Res 34: 520
41. Tahara H, Zeh HJ, Storkus WJ, Pappo I, Watkins SC, Gubler U, Wolf SF, Robbins PD, Lotze MT (1994) Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res 54: 182
42. Tahara H, Zitovogel L, Storkus WJ, Zeh HJ III, McKinney TG, Schreiber RD, Gubler U, Robbins PD, Lotze MT (1995) Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J Immunol 154: 6466
43. Trinchieri G (1994) Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood 84: 4008
44. Verbik DJ, Stinson WW, Brunda MJ, Kessinger A, Joshi SS (1995) Therapeutic effects of in vivo administration of interleukin-12 against residual lymphoma. Proc Am Assoc Cancer Res 36: 480
45. Voest EE, Kenyon BM, Truitt GA, O'Reilly MS, D'Amato RJ, Folkman J (1995) Interleukin 12 inhibits angiogenesis in vivo. J Natl Cancer Inst 87: 581
46. Wigginton JM, Komschlies KL, Back TC, Franco JL, Brunda MJ, Wiltrout RH (1996) Administration of interleukin-12 with pulse interleukin-2 and the rapid and complete eradication of murine renal carcinoma. J Natl Cancer Inst 88: 38
47. Wolf SF, Temple PA, Kobayashi M, Young D, Dicig M, Lowe L, Dzialo R, Fitz L, Ferenz C, Hewick RM, Kelleher K, Herrmann SH, Clark SC, Azzoni L, Chan SH, Trinchieri G, Perussia B (1991) Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells. J Immunol 146: 3074
48. Young HA, Hardy KJ (1995) Role of interferon-γ in immune cell regulation. J Leukocyte Biol 58: 373
49. Zitvogel L, Lotze MT (1995) Role of interleukin-12 (IL-12) as an antitumor agent: experimental biology and clinical application. Res Immunol 146: 628
50. Zitvogel L, Tahara H, Robbins PD, Storkus WJ, Clarke MR, Nalesnik MA, Lotze MT (1995) Cancer immunotherapy of established tumors with IL-12. Effective delivery by genetically engineered fibroblasts. J Immunol 155: 1393
51. Zou J-P, Yamamoto N, Fujii T, Takenaka H, Kobayashi M, Herrmann SH, Wolf SF, Fujiwara H, Hamaoka T (1995) Systemic administration of rIL-12 induces complete tumor regression and protective immunity: response is correlated with a striking reversal of suppressed IFN-γ production by anti-tumor T cells. Int Immunol 7: 1135